Pharming Group N.V. provided earnings guidance for the remainder of 2020. The company expects, Subject to progression of the COVID-19 pandemic in the US; continued growth in revenues from sales of RUCONEST®, mainly driven by the US and expanded EU operations. The company expects maintenance of positive net earnings during the year.